Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3039836 | 0.90 | TP53 (0.41) | ALDH1A1SMN1; SMN2KMT2ALMNATP53 | |
| SCHEMBL3041056 | 0.87 | KMT2A (0.38) | ALDH1A1SMN1; SMN2KMT2ALMNATP53 | |
| SCHEMBL5765900 | 0.84 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2LMNAMAPTRXFP1 | |
| SCHEMBL3035095 | 0.84 | MAOA (0.46) | ALDH1A1SMN1; SMN2LMNAMAPTRXFP1 | |
| SCHEMBL3043231 | 0.82 | CNR2 (0.39) | TP53GRM2MAPTKDM4EMAPK1 | |
| SCHEMBL3035077 | 0.81 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL3041143 | 0.77 | GRM2 (0.37) | TP53GRM2MAPTKDM4EMAPK1 | |
| SCHEMBL3036167 | 0.73 | MAOB (0.60) | LMNA | |
| SCHEMBL3043125 | 0.73 | GRM2 (0.44) | SMN1; SMN2KMT2ATP53GRM2MAPT | |
| SCHEMBL3035229 | 0.72 | GRM2 (0.41) | GRM2KDM4EMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645781-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER INC (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | THOMAS RICHARD C | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015801-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | ALDH1A1 956/4885SMN1; SMN2 2043/4885KMT2A 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.